Published in Proc Natl Acad Sci U S A on May 10, 2010
The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer (2012) 4.72
Controlling escape from angiogenesis inhibitors. Nat Rev Cancer (2012) 1.81
A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res (2011) 1.53
Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. Cancer Res (2012) 1.24
Can we unlock the potential of IGF-1R inhibition in cancer therapy? Cancer Treat Rev (2014) 1.16
Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer (2011) 1.12
Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation. Cell Mol Life Sci (2013) 1.08
Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling. Cell Rep (2016) 1.03
Insulin enhances metabolic capacities of cancer cells by dual regulation of glycolytic enzyme pyruvate kinase M2. Mol Cancer (2013) 1.02
Understanding the mechanism of insulin and insulin-like growth factor (IGF) receptor activation by IGF-II. PLoS One (2011) 1.01
Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer. Diabetes Care (2013) 1.00
MicroRNA-100 promotes the autophagy of hepatocellular carcinoma cells by inhibiting the expression of mTOR and IGF-1R. Oncotarget (2014) 0.99
New players for advanced prostate cancer and the rationalisation of insulin-sensitising medication. Int J Cell Biol (2013) 0.98
Targeting the insulin-like growth factor pathway in rhabdomyosarcomas: rationale and future perspectives. Sarcoma (2011) 0.96
Altered expression of insulin receptor isoforms in breast cancer. PLoS One (2011) 0.95
Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R. BMC Cancer (2014) 0.95
Combating resistance to anti-IGFR antibody by targeting the integrin β3-Src pathway. J Natl Cancer Inst (2013) 0.94
Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation. J Clin Endocrinol Metab (2013) 0.93
Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor. Breast Cancer Res Treat (2011) 0.93
Quantifying insulin receptor isoform expression in FFPE breast tumors. Growth Horm IGF Res (2012) 0.93
A twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factors. Int J Endocrinol (2013) 0.93
Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling. Crit Rev Oncog (2012) 0.92
Targeting IGF-1R: throwing out the baby with the bathwater? Br J Cancer (2011) 0.91
The insulin receptor negatively regulates the action of Pseudomonas toxin-based immunotoxins and native Pseudomonas toxin. Cancer Res (2013) 0.91
IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy. Mol Cancer Ther (2013) 0.91
Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance. Cancers (Basel) (2011) 0.90
Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor. PLoS One (2013) 0.89
A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal. Oncotarget (2013) 0.87
Insulin receptor isoform switching in intestinal stem cells, progenitors, differentiated lineages and tumors: evidence that IR-B limits proliferation. J Cell Sci (2013) 0.87
Insulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancer. Br J Cancer (2010) 0.86
Targeting IGF-1R: at a crossroad. Oncology (Williston Park) (2011) 0.85
Molecular targeted approaches for treatment of pancreatic cancer. Curr Pharm Des (2011) 0.85
Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer. PLoS One (2014) 0.85
Diet-induced metabolic change induces estrogen-independent allometric mammary growth. Proc Natl Acad Sci U S A (2012) 0.85
Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation. Front Endocrinol (Lausanne) (2015) 0.85
The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer. Adv Urol (2012) 0.84
Igf2 pathway dependency of the Trp53 developmental and tumour phenotypes. EMBO Mol Med (2012) 0.83
Organ-specific defects in insulin-like growth factor and insulin receptor signaling in late gestational asymmetric intrauterine growth restriction in Cited1 mutant mice. Endocrinology (2011) 0.83
Overexpression of the insulin receptor isoform A promotes endometrial carcinoma cell growth. PLoS One (2013) 0.83
Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with non-small-cell lung cancer. Clin Lung Cancer (2014) 0.83
Polymorphic genetic control of tumor invasion in a mouse model of pancreatic neuroendocrine carcinogenesis. Proc Natl Acad Sci U S A (2010) 0.82
Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cells. Oncogene (2016) 0.81
STAT3-mediated IGF-2 secretion in the tumour microenvironment elicits innate resistance to anti-IGF-1R antibody. Nat Commun (2015) 0.81
In vitro and in vivo models for analysis of resistance to anticancer molecular therapies. Curr Med Chem (2014) 0.81
Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer. World J Gastroenterol (2016) 0.81
Evaluation of a novel hexavalent humanized anti-IGF-1R antibody and its bivalent parental IgG in diverse cancer cell lines. PLoS One (2012) 0.81
Reduced insulin-like growth factor I receptor and altered insulin receptor isoform mRNAs in normal mucosa predict colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev (2014) 0.81
The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link. Front Endocrinol (Lausanne) (2015) 0.80
Insulin/Insulin-like growth factors in cancer: new roles for the aryl hydrocarbon receptor, tumor resistance mechanisms, and new blocking strategies. Front Endocrinol (Lausanne) (2015) 0.80
Emerging therapies in pancreas cancer. J Gastrointest Oncol (2011) 0.80
Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer. Mol Cancer (2015) 0.80
The Novel Functions of High-Molecular-Mass Complexes Containing Insulin Receptor Substrates in Mediation and Modulation of Insulin-Like Activities: Emerging Concept of Diverse Functions by IRS-Associated Proteins. Front Endocrinol (Lausanne) (2015) 0.79
Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. Semin Cancer Biol (2015) 0.79
Specific insulin/IGF1 hybrid receptor activation assay reveals IGF1 as a more potent ligand than insulin. Sci Rep (2015) 0.79
Deletion of intestinal epithelial insulin receptor attenuates high-fat diet-induced elevations in cholesterol and stem, enteroendocrine, and Paneth cell mRNAs. Am J Physiol Gastrointest Liver Physiol (2014) 0.78
Obesity and intestinal epithelial deletion of the insulin receptor, but not the IGF 1 receptor, affect radiation-induced apoptosis in colon. Am J Physiol Gastrointest Liver Physiol (2015) 0.77
Targeting the IGF-1R signaling and mechanisms for epigenetic gene silencing in human multiple myeloma. Ups J Med Sci (2012) 0.77
Expression of angiogenic growth factors in laryngeal carcinoma. Mol Clin Oncol (2013) 0.77
BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549. BMC Res Notes (2016) 0.77
Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R. Clin Cancer Res (2014) 0.77
Engineered ubiquitin ligase PTB-U-box targets insulin/insulin-like growth factor receptor for degradation and coordinately inhibits cancer malignancy. Oncotarget (2014) 0.77
Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. Clin Lung Cancer (2016) 0.76
Association between diabetes or antidiabetic therapy and lung cancer: A meta-analysis. J Diabetes Investig (2013) 0.76
IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights. Mol Cancer (2017) 0.76
Understanding the Key to Targeting the IGF Axis in Cancer: A Biomarker Assessment. Front Oncol (2015) 0.76
IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin. Oncotarget (2016) 0.76
Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. Endocr Relat Cancer (2015) 0.76
Can we negotiate with a tumor? PLoS One (2014) 0.76
Sexual dimorphism of liver metastasis by murine pancreatic neuroendocrine tumors is affected by expression of complement C5. Oncotarget (2016) 0.76
Type I insulin-like growth factor receptor signaling in hematological malignancies. Oncotarget (2017) 0.76
Intrinsic Resistance to Cixutumumab Is Conferred by Distinct Isoforms of the Insulin Receptor. Mol Cancer Res (2015) 0.75
Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer. BMC Cancer (2016) 0.75
CD24 cell surface expression in Mvt1 mammary cancer cells serves as a biomarker for sensitivity to anti-IGF1R therapy. Breast Cancer Res (2016) 0.75
Association of Bactericidal Dysfunction of Paneth Cells in Streptozocin-Induced Diabetic Mice with Insulin Deficiency. Med Sci Monit (2016) 0.75
Anticancer drugs: An unhelpful hand. Nat Rev Drug Discov (2010) 0.75
An unhelpful hand. Nat Rev Cancer (2010) 0.75
Involvement of Igf1r in Bronchiolar Epithelial Regeneration: Role during Repair Kinetics after Selective Club Cell Ablation. PLoS One (2016) 0.75
Molecular pathogenesis of pancreatic neuroendocrine tumors. Cancers (Basel) (2010) 0.75
MicroRNA-592 targets IGF-1R to suppress cellular proliferation, migration and invasion in hepatocellular carcinoma. Oncol Lett (2017) 0.75
Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms. Oncogene (2017) 0.75
IGF2 mRNA binding protein-2 is a tumor promoter that drives cancer proliferation through its client mRNAs IGF2 and HMGA1. Elife (2017) 0.75
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer (2008) 11.50
Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem (1999) 10.14
Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature (1985) 9.78
Gene expression profiles in normal and cancer cells. Science (1997) 9.65
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell (2005) 9.18
A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell (1998) 8.10
Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science (2003) 6.85
Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J (1986) 6.62
Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell (1999) 6.53
Insulin-like growth factors and neoplasia. Nat Rev Cancer (2004) 6.29
The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev (2006) 4.93
Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science (1999) 4.91
Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol (1999) 3.50
Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res (2007) 3.21
Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr (2007) 3.20
A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res (2003) 3.09
Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell (2002) 3.02
The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev (2000) 3.01
The IGF-1 receptor in cancer biology. Int J Cancer (2003) 2.66
A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature (1994) 2.51
The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res (2006) 2.48
Analysis of the Cre-mediated recombination driven by rat insulin promoter in embryonic and adult mouse pancreas. Genesis (2000) 2.48
The IGF system and breast cancer. Endocr Relat Cancer (2001) 2.21
The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem (2008) 2.20
Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene (2009) 2.17
Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Mol Cancer Ther (2009) 2.16
Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem (2002) 2.15
Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res (2010) 2.13
Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci U S A (1995) 2.09
Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem (2008) 1.89
The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res (2009) 1.78
IGF1R signalling and its inhibition. Endocr Relat Cancer (2006) 1.77
Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol (2003) 1.72
Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene (1999) 1.66
BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther (2009) 1.62
Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res (2007) 1.61
A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res (1998) 1.60
Insulin receptor expression by human prostate cancers. Prostate (2009) 1.57
Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res (2001) 1.55
Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst (2007) 1.53
Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res (1993) 1.51
Receptors for insulin and insulin-like growth factor-I can form hybrid dimers. Characterisation of hybrid receptors in transfected cells. Biochem J (1990) 1.49
Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor. Diabetologia (1997) 1.45
Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling. Endocrinology (2002) 1.45
Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. Proc Natl Acad Sci U S A (2009) 1.45
A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab (2002) 1.44
The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des (2007) 1.43
Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol Cancer Ther (2006) 1.43
Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res (2009) 1.37
IGF and insulin receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia (2008) 1.36
Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Res (1972) 1.35
Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc Natl Acad Sci U S A (1976) 1.32
Insulin receptor expression and function in human breast cancer cell lines. Cancer Res (1992) 1.31
Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene (2010) 1.23
Insulin, insulin-like growth factors, insulin resistance, and neoplasia. Am J Clin Nutr (2007) 1.15
Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice. J Natl Cancer Inst (1981) 1.13
Harnessing preclinical mouse models to inform human clinical cancer trials. J Clin Invest (2006) 1.06
Obesity and cancer. Nutr Metab Cardiovasc Dis (2006) 1.00
IGF2 loss of imprinting: a potential heritable risk factor for colorectal cancer. Gastroenterology (2004) 0.97
The insulin receptor as a transmitter of a mitogenic signal in Chinese hamster ovary CHO-K1 cells. Proc Natl Acad Sci U S A (1989) 0.93
Insulin stimulates haptotactic migration of human epidermal keratinocytes through activation of NF-kappa B transcription factor. J Cell Sci (1997) 0.91
Differential contribution to neuroendocrine tumorigenesis of parallel egfr signaling in cancer cells and pericytes. Genes Cancer (2010) 0.90
The receptor for the type I insulin-like growth factor and its ligands regulate multiple cellular functions that impact on metastasis. Surg Oncol Clin N Am (2001) 0.88
Functional evaluation of novel soluble insulin-like growth factor (IGF)-II-specific ligand traps based on modified domain 11 of the human IGF2 receptor. Mol Cancer Ther (2007) 0.87
Insulin-like growth factor II is focally up-regulated and functionally involved as a second signal for oncogene-induced tumorigenesis. Cold Spring Harb Symp Quant Biol (1994) 0.81
Identification and importance of brown adipose tissue in adult humans. N Engl J Med (2009) 20.57
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A (2003) 17.10
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20
Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol (2006) 10.67
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell (2005) 9.18
Developmental origin of fat: tracking obesity to its source. Cell (2007) 8.80
Extended longevity in mice lacking the insulin receptor in adipose tissue. Science (2003) 8.53
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest (2003) 8.34
Suppression of aging in mice by the hormone Klotho. Science (2005) 8.11
Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab (2008) 7.97
New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. Nature (2008) 6.82
SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature (2010) 6.48
Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer Cell (2010) 6.33
A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med (2013) 6.09
Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A (2006) 5.90
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev (2006) 5.53
Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci U S A (2009) 5.19
Beneficial effects of subcutaneous fat transplantation on metabolism. Cell Metab (2008) 5.07
Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell (2002) 5.01
Evidence for a role of developmental genes in the origin of obesity and body fat distribution. Proc Natl Acad Sci U S A (2006) 4.81
From mice to men: insights into the insulin resistance syndromes. Annu Rev Physiol (2006) 4.58
Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A (2006) 4.51
Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell (2004) 4.38
Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell (2002) 4.35
Cellular bioenergetics as a target for obesity therapy. Nat Rev Drug Discov (2010) 4.23
GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev (2009) 4.21
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med (2011) 4.10
An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest (2004) 4.03
Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell (2009) 4.02
Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell (2007) 3.82
A guide to analysis of mouse energy metabolism. Nat Methods (2011) 3.82
Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol (2004) 3.79
Insulin action in AgRP-expressing neurons is required for suppression of hepatic glucose production. Cell Metab (2007) 3.69
Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med (2008) 3.66
Loss of ARNT/HIF1beta mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes. Cell (2005) 3.52
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol (2004) 3.40
Ectopic brown adipose tissue in muscle provides a mechanism for differences in risk of metabolic syndrome in mice. Proc Natl Acad Sci U S A (2007) 3.40
Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab (2006) 3.34
SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell (2011) 3.33
Endocrine regulation of ageing. Nat Rev Mol Cell Biol (2007) 3.28
VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell (2002) 3.27
A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res (2003) 3.09
Retracted Positive and negative roles of p85 alpha and p85 beta regulatory subunits of phosphoinositide 3-kinase in insulin signaling. J Biol Chem (2003) 3.06
Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab (2010) 3.05
Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell (2002) 3.02
Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest (2003) 2.87
Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat Med (2012) 2.86
Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. Cell Metab (2006) 2.82
The emerging genetic architecture of type 2 diabetes. Cell Metab (2008) 2.77
Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev (2006) 2.74
Effects of diet and genetic background on sterol regulatory element-binding protein-1c, stearoyl-CoA desaturase 1, and the development of the metabolic syndrome. Diabetes (2005) 2.72
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res (2002) 2.69
Prediction of preadipocyte differentiation by gene expression reveals role of insulin receptor substrates and necdin. Nat Cell Biol (2005) 2.68
Platform-independent and label-free quantitation of proteomic data using MS1 extracted ion chromatograms in skyline: application to protein acetylation and phosphorylation. Mol Cell Proteomics (2012) 2.66
Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J Clin Invest (2002) 2.65
Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell (2003) 2.56
PDX-1 haploinsufficiency limits the compensatory islet hyperplasia that occurs in response to insulin resistance. J Clin Invest (2004) 2.56
Genetic determinants of energy expenditure and insulin resistance in diet-induced obesity in mice. Diabetes (2004) 2.54
Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci U S A (2004) 2.54
Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A (2004) 2.54
Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J Clin Invest (2002) 2.53
Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A (2001) 2.49
Phlorizin: a review. Diabetes Metab Res Rev (2005) 2.48
Impaired insulin/IGF1 signaling extends life span by promoting mitochondrial L-proline catabolism to induce a transient ROS signal. Cell Metab (2012) 2.43
Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol Cell Biol (2002) 2.42
SIRT2 regulates adipocyte differentiation through FoxO1 acetylation/deacetylation. Cell Metab (2007) 2.42
Sirtuin-3 (Sirt3) regulates skeletal muscle metabolism and insulin signaling via altered mitochondrial oxidation and reactive oxygen species production. Proc Natl Acad Sci U S A (2011) 2.41
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev (2009) 2.41
Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med (2008) 2.40
Analysis of gene expression in pathophysiological states: balancing false discovery and false negative rates. Proc Natl Acad Sci U S A (2006) 2.32
Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science (2002) 2.28
Total insulin and IGF-I resistance in pancreatic beta cells causes overt diabetes. Nat Genet (2006) 2.21
Mir193b-365 is essential for brown fat differentiation. Nat Cell Biol (2011) 2.20
Muscle-specific knockout of PKC-lambda impairs glucose transport and induces metabolic and diabetic syndromes. J Clin Invest (2007) 2.17
Endogenous Myc maintains the tumor microenvironment. Genes Dev (2011) 2.16
Mouse models of insulin resistance. Physiol Rev (2004) 2.16
Differential roles of insulin receptor substrates in brown adipocyte differentiation. Mol Cell Biol (2004) 2.14
Of mice and MEN1: Insulinomas in a conditional mouse knockout. Mol Cell Biol (2003) 2.12
The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J Clin Invest (2003) 2.11
Deficiency of PDK1 in cardiac muscle results in heart failure and increased sensitivity to hypoxia. EMBO J (2003) 2.11
Dissection of the insulin signaling pathway via quantitative phosphoproteomics. Proc Natl Acad Sci U S A (2008) 2.11
Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. Cell Metab (2010) 2.09
Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell (2013) 2.09
Skeletal muscle-selective knockout of LKB1 increases insulin sensitivity, improves glucose homeostasis, and decreases TRB3. Mol Cell Biol (2006) 2.09
Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell (2003) 2.07
Lessons on conditional gene targeting in mouse adipose tissue. Diabetes (2013) 2.04
Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest (2005) 2.01
Label-free quantitative proteomics of the lysine acetylome in mitochondria identifies substrates of SIRT3 in metabolic pathways. Proc Natl Acad Sci U S A (2013) 2.01
Central insulin action regulates peripheral glucose and fat metabolism in mice. J Clin Invest (2008) 2.00
The cellular fate of glucose and its relevance in type 2 diabetes. Endocr Rev (2004) 1.98
Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation. Biochem J (2011) 1.96
A regulatory subunit of phosphoinositide 3-kinase increases the nuclear accumulation of X-box-binding protein-1 to modulate the unfolded protein response. Nat Med (2010) 1.93
Muscle-specific Pten deletion protects against insulin resistance and diabetes. Mol Cell Biol (2005) 1.93
Brown fat as a therapy for obesity and diabetes. Curr Opin Endocrinol Diabetes Obes (2010) 1.93
Intrinsic differences in adipocyte precursor cells from different white fat depots. Diabetes (2012) 1.91
IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res (2007) 1.87
Coordinated patterns of gene expression for substrate and energy metabolism in skeletal muscle of diabetic mice. Proc Natl Acad Sci U S A (2002) 1.86
Akt signaling mediates postnatal heart growth in response to insulin and nutritional status. J Biol Chem (2002) 1.86